TY - JOUR
T1 - The National Marrow Donor Program's Symposium on Hematopoietic Cell Transplantation in 2020
T2 - A Health Care Resource and Infrastructure Assessment
AU - Majhail, Navneet S.
AU - Murphy, Elizabeth A.
AU - Denzen, Ellen M.
AU - Ferguson, Stacy S.
AU - Anasetti, Claudio
AU - Bracey, Arthur
AU - Burns, Linda
AU - Champlin, Richard
AU - Hubbard, Norman
AU - Markowitz, Miriam
AU - Maziarz, Richard T.
AU - Medoff, Erin
AU - Neumann, Joyce
AU - Schmit-Pokorny, Kim
AU - Weisdorf, Daniel J
AU - Yolin Raley, Deborah S.
AU - Chell, Jeffrey
AU - Snyder, Edward L.
PY - 2012/2
Y1 - 2012/2
N2 - Hematopoietic cell transplantation (HCT) is the only known curative therapy for many patients with life-threatening hematologic and oncologic diseases. It is estimated that the National Marrow Donor Program® (NMDP) will facilitate 10,000 transplants by 2015, double the current number. To better understand the existing personnel and center infrastructure for HCT in the country and to address system capacity challenges to the future growth of HCT, the NMDP convened a diverse group of stakeholders and thought leaders representing HCT physicians, physician assistants, nurse practitioners, nurses, pharmacists, other healthcare providers, HCT program directors, hospital administrators, payors, and professional organizations. Working groups were formed to identify: capacity issues because of shortages in human resources, structural constraints, and patient access barriers including diversity and healthcare disparity challenges; recommendations to address challenges; and stakeholders to engage. This report details the deliberations and recommendations of a national symposium, " Hematopoietic Cell Transplantation in 2020: A Health Care Resource and Infrastructure Assessment," held in September 2010.
AB - Hematopoietic cell transplantation (HCT) is the only known curative therapy for many patients with life-threatening hematologic and oncologic diseases. It is estimated that the National Marrow Donor Program® (NMDP) will facilitate 10,000 transplants by 2015, double the current number. To better understand the existing personnel and center infrastructure for HCT in the country and to address system capacity challenges to the future growth of HCT, the NMDP convened a diverse group of stakeholders and thought leaders representing HCT physicians, physician assistants, nurse practitioners, nurses, pharmacists, other healthcare providers, HCT program directors, hospital administrators, payors, and professional organizations. Working groups were formed to identify: capacity issues because of shortages in human resources, structural constraints, and patient access barriers including diversity and healthcare disparity challenges; recommendations to address challenges; and stakeholders to engage. This report details the deliberations and recommendations of a national symposium, " Hematopoietic Cell Transplantation in 2020: A Health Care Resource and Infrastructure Assessment," held in September 2010.
KW - Hematopoietic cell transplantation
KW - National Marrow Donor Program
KW - System capacity
KW - Workforce shortage
UR - http://www.scopus.com/inward/record.url?scp=84855612460&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84855612460&partnerID=8YFLogxK
U2 - 10.1016/j.bbmt.2011.10.004
DO - 10.1016/j.bbmt.2011.10.004
M3 - Article
C2 - 22178961
AN - SCOPUS:84855612460
SN - 1083-8791
VL - 18
SP - 172
EP - 182
JO - Biology of Blood and Marrow Transplantation
JF - Biology of Blood and Marrow Transplantation
IS - 2
ER -
